Scopus
YÖKSİS Eşleşti
Pharmacokinetics of enrofloxacin and danofloxacin in premature calves
Journal of Veterinary Pharmacology and Therapeutics · Kasım 2019
YÖKSİS Kayıtları
Pharmacokinetics of enrofloxacin and danofloxacin in premature calves
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS · 2019 SCI
PROFESÖR MAHMUT OK →
Pharmacokinetics of enrofloxacin and danofloxacin in premature calves
Journal of Veterinary Pharmacology and Therapeutics · 2019 SCI-Expanded
DOÇENT MERVE İDER →
Pharmacokinetics of enrofloxacin and danofloxacin in premature calves
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS · 2019 SCI
PROFESÖR KAMİL ÜNEY →
Makale Bilgileri
DergiJournal of Veterinary Pharmacology and Therapeutics
Yayın TarihiKasım 2019
Cilt / Sayfa42 · 624-631
Scopus ID2-s2.0-85067616256
Özet
The aim of this study was to determine the pharmacokinetics/pharmacodynamics of enrofloxacin (ENR) and danofloxacin (DNX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. The study was performed on twenty-four calves that were determined to be premature by anamnesis and general clinical examination. Premature calves were randomly divided into four groups (six premature calves/group) according to a parallel pharmacokinetic (PK) design as follows: ENR-IV (10 mg/kg, IV), ENR-IM (10 mg/kg, IM), DNX-IV (8 mg/kg, IV), and DNX-IM (8 mg/kg, IM). Plasma samples were collected for the determination of tested drugs by high-pressure liquid chromatography with UV detector and analyzed by noncompartmental methods. Mean PK parameters of ENR and DNX following IV administration were as follows: elimination half-life (t<inf>1/2λz</inf>) 11.16 and 17.47 hr, area under the plasma concentration–time curve (AUC<inf>0-48</inf>) 139.75 and 38.90 hr*µg/ml, and volume of distribution at steady-state 1.06 and 4.45 L/kg, respectively. Total body clearance of ENR and DNX was 0.07 and 0.18 L hr<sup>−1</sup> kg<sup>−1</sup>, respectively. The PK parameters of ENR and DNX following IM injection were t<inf>1/2λz</inf> 21.10 and 28.41 hr, AUC<inf>0-48</inf> 164.34 and 48.32 hr*µg/ml, respectively. The bioavailability (F) of ENR and DNX was determined to be 118% and 124%, respectively. The mean AUC<inf>0-48CPR</inf>/AUC<inf>0-48ENR</inf> ratio was 0.20 and 0.16 after IV and IM administration, respectively, in premature calves. The results showed that ENR (10 mg/kg) and DNX (8 mg/kg) following IV and IM administration produced sufficient plasma concentration for AUC<inf>0-24</inf>/minimum inhibitory concentration (MIC) and maximum concentration (C<inf>max</inf>)/MIC ratios for susceptible bacteria, with the MIC<inf>90</inf> of 0.5 and 0.03 μg/ml, respectively. These findings may be helpful in planning the dosage regimen for ENR and DNX, but there is a need for further study in naturally infected premature calves.
Yazarlar (6)
1
Orhan Corum
ORCID: 0000-0003-3168-2510
2
Feray Altan
3
Ramazan Yildiz
4
Merve Ider
ORCID: 0000-0003-2928-5452
5
M. Ok
6
Kamil Üney
ORCID: 0000-0002-8674-4873
Anahtar Kelimeler
bioavailability
danofloxacin
enrofloxacin
pharmacokinetics
premature calves
Kurumlar
Burdur Mehmet Akif Ersoy Üniversitesi
Burdur Turkey
Dicle Üniversitesi
Diyarbakir Turkey
Kastamonu University
Kastamonu Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
14
Atıf
6
Yazar
5
Anahtar Kelime